Vectura has announced that it will partner with Janssen Biotech to develop inhaled dry powder anti-inflammatory products for the treatment of asthma and COPD. Janssen’s drug candidates will be developed using Vectura’s DPI delivery technology, with Janssen taking responsibility for clinical development and Vectura having responsibility for pharmaceutical development.
According to Vectura, the value of the development and licensing deal is undisclosed but includes an upfront payment, development milestones, and tiered royalties.
Vectura CEO Chris Blackwell said, “Vectura’s role in this agreement is to apply its expertise in the development of products for airway-related diseases and to utilize its technology/device platform offerings, some of which have regulatory and commercial validation. Vectura continues to be viewed as a partner of choice by companies seeking to address the unmet medical needs of patients with airway diseases.”
Read the Vectura press release.
